<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994929</url>
  </required_header>
  <id_info>
    <org_study_id>PRO08070154, Wyeth 3067K1-2214</org_study_id>
    <nct_id>NCT00994929</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of IL-11 in DDAVP Unresponsive</brief_title>
  <acronym>IL-11DDAVP</acronym>
  <official_title>Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the biologic efficacy and safety of rhIL-11 when
      given subcutaneously in adults with moderate or mild hemophilia A or Von Willebrand disease
      unresponsive to DDAVP. Biologic efficacy will be measured by the number and percent increase
      of VWD coagulation tests (FVIII:C, VWF: Ag, VWF: RCo, closure time, APTT, and VWF multimers)
      to the normal range, or at least to 1.5-3 time baseline, following dosing of rhIL-11 when
      given daily for 4 days, and boosted by DDAVP infusion on day 4, in those in whom DDAVP is not
      contraindicated. Safety will be measured by the frequency of adverse events, including fever,
      headache, fatigue, myalgias, arthralgias, fluid retention, or edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single center, Phase II biologic effects study of recombinant
      interleukin-11 (rhIL-11, Neumega) in subjects hemophilia A, moderate or mild; or with Von
      Willebrand disease unable to take desmopressin acetate (DDAVP) because they are unresponsive,
      allergic, or DDAVP is contraindicated. The purpose of the study is to establish the biologic
      efficacy and safety of rhIL-11 in those not able to take DDAVP. Study subjects will include
      adults, age &gt;= 18 years, with hemophilia A, moderate, defined as factor VIII 0.01-0.04 U/ml,
      or mild, defined as factor VIII &gt;= 0.05 U/ml; or with VWD defined by low VWF:RCo and /or low
      VWF:Ag, past bleeding history, and/or family history of VWD. A total of 10-16 subjects will
      be enrolled in order to assure that 10 complete the study. The specific aims of the study
      are: 1) to determine the biologic effect of rhIL-11 when given 4 consecutive days; 2) to
      determine the safety of rhIL-11 when used in subjects with hemophilia A, moderate or mild; or
      with VWD unresponsive or unable to take DDAVP; and 3) to determine the mechanism of the
      hemostatic effects of rhIL-11. The biologic efficacy outcomes will be measured by VWD-related
      coagulation tests (VWF:RCo, FVIII:C, VWF:Ag, closure times) before and after rhIL-11
      injection. Safety outcomes will be measured by the number and frequency of adverse events,
      including fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema. The
      mechanism of rhIL-11 hemostatic effect will be measured by VWFmRNA before and after rhIL-11
      response. Response to DDAVP following rhIL-11 will also be assessed in those in whom DDAVP is
      not contraindicated. The study will last up to 1 month per subject, and for 24 months for the
      entire study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biologic Effects by Coagulation Tests</measure>
    <time_frame>within 4 days of study drug.</time_frame>
    <description>VWF activity was measured by ristocetin-induced platelet agglutination using a Chronolog aggregometer11-14 and VWF:Ag by &quot;sandwich&quot; ELISA, using anti-VWF antibodies (DakoA082, Carpintera CA). Results were expressed in percent, with normal human plasma pool designated 100%, and severe type 3 VWD plasma used as the negative control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Frequency of Adverse Events</measure>
    <time_frame>within 11 days of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mechanism of Study Drug Effect by VWF mRNA.</measure>
    <time_frame>within 11 days of study drug.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>Neumega (Oprelveken, Interleukin 11)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neumega (Oprelvekin, Interleukin 11, IL-11)</intervention_name>
    <description>25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.</description>
    <arm_group_label>Neumega (Oprelveken, Interleukin 11)</arm_group_label>
    <other_name>Interleukin-11</other_name>
    <other_name>IL-11</other_name>
    <other_name>Oprelvekin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females &gt;= 18 years of age.

          -  A diagnosis of hemophilia A, moderate (FVIII:C 0.01-0.04 U/ml) or mild (FVIII:C &gt;=
             0.05 U/ml); or a diagnosis of VWD, defined by a low VWF:RCo and past bleeding history.

          -  For those with VWD, an inability to use DDAVP due to i) unresponsiveness defined as
             VWF:RCo or FVIII:C level lower than 50 IU/dl or less than a 3-fold increase after 0.3
             microgram/kg DDAVP; ii) allergic reactions or seizures; or iii) a contraindication to
             DDAVP.

          -  Willingness to have blood drawn.

          -  Willingness to sign informed consent.

        Exclusion Criteria:

          -  Presence of other bleeding disorders, acquired Von Willebrand disease, primary
             thrombocytopenia.

          -  Use of immunomodulatory or experimental drugs, or diuretics.

          -  Pregnant or lactating women.

          -  Previous cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation,
             atrial flutter), hypertension, MI, stroke, or thrombosis.

          -  Past allergic reaction to Neumega.

          -  Surgery within the past 8 weeks.

          -  Inability to comply with study protocol requirements.

          -  Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs.

          -  Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives
             containing substantial quantities of FVIII and/or VWF within five days of study.

          -  Baseline safety and/or hematology lab values outside the normal limits and/or an EKG
             indicating an arrhythmia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret V. Ragni, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ragni MV, Jankowitz RC, Chapman HL, Merricks EP, Kloos MT, Dillow AM, Nichols TC. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia. 2008 Sep;14(5):968-77. doi: 10.1111/j.1365-2516.2008.01827.x. Epub 2008 Aug 1.</citation>
    <PMID>18680527</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2016</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Margaret Ragni</investigator_full_name>
    <investigator_title>Laurel Yasko</investigator_title>
  </responsible_party>
  <keyword>biologic effects</keyword>
  <keyword>von Willebrand disease</keyword>
  <keyword>hemophilia</keyword>
  <keyword>interleukin-11</keyword>
  <keyword>DDAVp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
    <mesh_term>Oprelvekin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Nine (9) subjects 18 years or older, including five with mild or moderate hemophilia A (HA) and four with mild or moderate von Willebrand disease (VWD) unresponsive or allergic to DDAVP were enrolled in and completed the study between January 2010 and February 2012.</recruitment_details>
      <pre_assignment_details>Following enrollment, subjects initiated study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Neumega (Oprelveken, Interleukin 11)</title>
          <description>25 µg/kilogram of body weight of rhIL-11 subcutaneously administered on days 1 to 4. On day 4 following rhIL-11 injection DDAVP was subsequently given at 0.3 mcg/kg intravenously over 30 minutes. For any subject with past allergic reactions, hypersensitivity, or seizures with DDAVP, or in whom DDAVP is contraindicated, DDAVP was not given: only rhIL-11 was given on Day 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>5 subjects were mild or moderate hemophilia A; 4 were mild or moderate VWD; all unresponsive or allergic to DDAVP The VWD subjects - 2, type 1 and 2, type 2 VWD, including one with type 2B, and one with type 2M. All subjects had positive past bleeding histories.</population>
      <group_list>
        <group group_id="B1">
          <title>Neumega (Oprelveken, Interleukin 11)</title>
          <description>The VWD subjects included two with type 1 VWD and two with type 2 VWD, including one with type 2B, with increased platelet aggregation at low strength ristocetin and absent high molecular weight multimers, and one with type 2M disease, with reduced VWF:RCoF/ VWF:Ag ratio &lt;0.50, per NHLBI criteria (Table 2).5 All subjects had positive past bleeding histories. Pregnancy, lactation, heart disease, uncontrolled hypertension, arrhythmia, thrombosis, recent surgery or receipt of blood products were exclusions. A total of nine subjects were enrolled and completed study, including five with hemophilia A and four with VWD. The median age was 26 years, range 22-51 years</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="22" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biologic Effects by Coagulation Tests</title>
        <description>VWF activity was measured by ristocetin-induced platelet agglutination using a Chronolog aggregometer11-14 and VWF:Ag by “sandwich” ELISA, using anti-VWF antibodies (DakoA082, Carpintera CA). Results were expressed in percent, with normal human plasma pool designated 100%, and severe type 3 VWD plasma used as the negative control</description>
        <time_frame>within 4 days of study drug.</time_frame>
        <population>Four subjects had VWD and five subjects had mild hemophilia A</population>
        <group_list>
          <group group_id="O1">
            <title>Neumega (Oprelveken, Interleukin 11)</title>
            <description>Neumega (Oprelvekin, Interleukin 11, IL-11): 25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.</description>
          </group>
        </group_list>
        <measure>
          <title>Biologic Effects by Coagulation Tests</title>
          <description>VWF activity was measured by ristocetin-induced platelet agglutination using a Chronolog aggregometer11-14 and VWF:Ag by “sandwich” ELISA, using anti-VWF antibodies (DakoA082, Carpintera CA). Results were expressed in percent, with normal human plasma pool designated 100%, and severe type 3 VWD plasma used as the negative control</description>
          <population>Four subjects had VWD and five subjects had mild hemophilia A</population>
          <units>percentage of normal</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VWD patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.75" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild hemophilia A patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.4" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Frequency of Adverse Events</title>
        <time_frame>within 11 days of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neumega (Oprelveken, Interleukin 11)</title>
            <description>Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
Neumega (Oprelvekin, Interleukin 11, IL-11): 25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.</description>
          </group>
        </group_list>
        <measure>
          <title>The Frequency of Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mechanism of Study Drug Effect by VWF mRNA.</title>
        <time_frame>within 11 days of study drug.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neumega (Oprelveken, Interleukin 11)</title>
            <description>Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
Neumega (Oprelvekin, Interleukin 11, IL-11): 25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mechanism of Study Drug Effect by VWF mRNA.</title>
          <units>fold increase</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="-0.07" upper_limit="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>January 2010 to February 2012</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Neumega (Oprelveken, Interleukin 11)</title>
          <description>Neumega (Oprelvekin, Interleukin 11, IL-11): 25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed on day 4 by DDAVP 0.3 microgram/kg by intravenous infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Infection</sub_title>
                <description>Grade 1 or less</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flu-Like Symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Hyponatremia occurred in a diabetic patient after excess fluid intake for symptomatic hyperglycemia, which resolved with fluid restriction. Hyponatremia was grade 3 (129 mEq/L).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>One of the two patients with thrombocytopenia was the 2B VWD patient, whose baseline platelet count was low and remained unchanged after rhIL-11.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Margaret V. Ragni, MD, MPH</name_or_title>
      <organization>The University of Pittsburgh</organization>
      <phone>412-209-7288</phone>
      <email>ragni@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

